Patents by Inventor Mark Sonders

Mark Sonders has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7381542
    Abstract: The present invention relates to novel mammalian biogenic amine receptor proteins and genes that encode such proteins. The invention is directed toward the isolation and characterization of mammalian trace amine receptor proteins. The invention specifically provides isolated complementary DNA copies of mRNA corresponding to rat and human homologues of a mammalian trace amine receptor gene. Also provided are recombinant expression constructs capable of expressing the mammalian trace amine receptor genes of the invention in cultures of transformed prokaryotic and eukaryotic cells, as well as such cultures of transformed cells that synthesize the mammalian trace amine receptor proteins encoded therein.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: June 3, 2008
    Assignee: Oregon Health & Science University
    Inventors: James Bunzow, David K. Grandy, Mark Sonders
  • Publication number: 20040072187
    Abstract: The present invention relates to novel mammalian biogenic amine receptor proteins and genes that encode such proteins. The invention is directed toward the isolation and characterization of mammalian trace amine receptor proteins. The invention specifically provides isolated complementary DNA copies of mRNA corresponding to rat and human homologues of a mammalian trace amine receptor gene. Also provided are recombinant expression constructs capable of expressing the mammalian trace amine receptor genes of the invention in cultures of transformed prokaryotic and eukaryotic cells, as well as such cultures of transformed cells that synthesize the mammalian trace amine receptor proteins encoded therein.
    Type: Application
    Filed: August 4, 2003
    Publication date: April 15, 2004
    Inventors: James Bunzow, David K. Grandy, Mark Sonders
  • Patent number: 4709094
    Abstract: 1,3-Disubstituted-guanidines, e.g., of the formula ##STR1## wherein R and R' are hydrocarbon groups which preferably are the same, e.g., 1,3-dibutyl-guanidine, 1,3-diphenyl-guanidine and 1,3-di-o-tolyl-guanidine, are highly selective ligands for sigma brain receptors and are useful in the diagnosis and treatment of hallucination associated psychotic mental illness and chronic mental depression. Tritium labeled 1,3-di-(o-tolyl)-guanidine is useful as a screening tool for compounds having selective sigma receptor binding activity, as it is displaced from isolated mammalian brain membrane to which it is bound portionately to the activity of such a compound.
    Type: Grant
    Filed: July 10, 1986
    Date of Patent: November 24, 1987
    Assignee: State of Oregon, acting by and through the Oregon State Board of Higher Education, acting for and on behalf of the Oregon Health Sciences University and the University of Oregon
    Inventors: Eckard Weber, Mark Sonders, John F. Keana